Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro
- 1 January 1989
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 25 (1) , 32-36
- https://doi.org/10.1007/bf00694335
Abstract
Summary We examined the ability of lonidamine, which has been described as an inhibitor of cellular respiration and glycolysis, to enhance the cytotoxicity of alkylating agents to MCF-7 human breast-carcinoma cells. Lonidamine was increasingly cytotoxic to MCF-7 cells with increasing time of exposure. With a 12-h exposure, the IC50 for lonidamine was about 365 μM, and with a 24-h exposure it was about 170 μM. A drug concentration of 250 μM was chosen for use in the drug combination studies. Lonidamine appeared to have a dose-modifying effect on cisplatin (CDDP), producing increasingly supraadditive cell kill with increasing CDDP concentration. When simultaneously incubated with lonidamine for 1 h, 500 μM CDDP yielded a cell kill that was 2 log greater than additive cytotoxicity. Extending the exposure to lonidamine for 12 h after CDDP treatment led to a small, additional aliquot of cell kill of about 2.5-fold over the CDDP concentration range. Lonidamine also appeared to have a dose-modifying effect on melphalan cytotoxicity in the melphalan concentration range of 100–500 μM. Between concentrations of 10 and 100 μM melphalan, the drug combination survival after 1 h exposure fell within the envelope of additivity for the two agents. However, maintaining the presence of lonidamine for an additional 12 h increased the effect such that the combination was supraadditive over the entire concentration range of melphalan. Simultaneous exposure to 4-hydroperoxycyclophosphamide (4-HC) and lonidamine for 1 h resulted in greater than additive cell kill, and extending the lonidamine exposure period such that lonidamine was present during and 12 h after 4-HC treatment further increased this effect. Lonidamine had a moderate effect on the cytotoxicity of carmustine (BCNU) with a 1 h simultaneous exposure; however, this treatment combination reached greater than additive cytotoxicity only at the highest concentration of BCNU tested. Extending the lonidamine exposure time for an additional 12 h resulted in supraadditive cell kill over the BCNU concentration range. Therefore, when lonidamine was present during exposure to the alkylating agent and its presence was then extended for an additional 12 h, a synergistic cell kill was produced with all four alkylating agents tested.Keywords
This publication has 22 references indexed in Scilit:
- Cell membrane changes induced by Lonidamine in human erythrocytes and T lymphocytes, and ehrlich ascites tumor cellsExperimental and Molecular Pathology, 1987
- Radiosensitization of Meth-A Fibrosarcoma in Mice by LonidamineOncology, 1984
- Lonidamine and Hyperthermia: Clinical Experience in MelanomaOncology, 1984
- Lonidamine and Radiotherapy in Head and Neck CancersOncology, 1984
- Lonidamine Alone and in Combination with Other Chemotherapeutic Agents in the Treatment of Cancer PatientsOncology, 1984
- Phase II Evaluation of Lonidamine in Patients with Advanced MalignancyOncology, 1984
- Phase II Study of Lonidamine in Cancer PatientsOncology, 1984
- Lonidamine: A Hyperthermic Sensitizer of HeLa Cells in Culture and of the Meth-A Tumor in vivoOncology, 1984
- Effects of Lonidamine on Murine and Human Tumor Cells in vitroOncology, 1984
- Exploitable mechanisms in combined radiotherapy-chemotherapy: The concept of additivityInternational Journal of Radiation Oncology*Biology*Physics, 1979